 SEATTLE, WA ACCESSWIRE June 25, 2020 Aptevo Therapeutics Inc. APVO, a biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM bispecific technology platform, today announced that it will receive a royalty from Pfizer related to sales of a rituximab biosimilar product, RUXIENCE Rituximab-pvvr, which was approved by the U.S. Food and Drug Administration in July 2019 and launched by Pfizer in the United States and Japan in early 2020. We are pleased to be receiving this first royalty payment from Pfizer and look forward to future quarterly payments, all of which will contribute non-dilutive funding to support our organization, said Marvin L. White, President and Chief Executive Officer. 